Welcome to our dedicated page for Agilent Technologies SEC filings (Ticker: A), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agilent Technologies Inc. (NYSE: A) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports when available, and other filings that describe Agilent’s financial condition, governance changes, and capital markets activities.
Agilent uses Form 8-K to report material events such as quarterly financial results and executive leadership changes. For example, the company has filed 8-Ks to furnish earnings press releases for fiscal quarters, explaining revenue, net income, segment performance for the Life Sciences and Diagnostics Markets Group, Agilent CrossLab Group, and Applied Markets Group, and to discuss the use of non-GAAP financial measures. Separate 8-K filings describe the resignation of a chief financial officer, the appointment of an interim CFO, and the subsequent appointment of a new senior vice president and chief financial officer, including related compensation and equity awards.
Through its filings, Agilent explains why it presents non-GAAP financial information, stating that these measures are intended to provide meaningful supplemental insight into operational performance and to facilitate comparisons with historical results and other companies. The company notes that non-GAAP figures exclude items such as restructuring and amortization, are monitored alongside GAAP results, and may differ from similar measures used by other issuers.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that highlight key points, such as changes in leadership, segment trends, and the rationale behind non-GAAP adjustments. Users can quickly locate current reports, review disclosures about executive appointments and compensation arrangements, and understand how Agilent communicates its financial performance and governance decisions to regulators and investors.
Form 144 notice for Agilent Technologies Inc. (symbol: A) reports a proposed sale of 5,781 common shares through Fidelity Brokerage Services on 09/09/2025 with an aggregate market value of $729,591.11. The shares were acquired on 11/15/2022 upon restricted stock vesting and were issued as compensation. The filing also discloses prior sales by Robert W. McMahon of 28,081 shares on 08/29/2025 for $3,508,994.14 and 15,303 shares on 09/04/2025 for $1,968,223.83. The total shares outstanding reported in the form are 283,500,427. Several administrative fields such as filer CIK and issuer address are not provided in the text.
Form 144 notice for Agilent Technologies, Inc. (A) discloses a proposed sale of 15,303 common shares through Fidelity Brokerage Services (NYSE) with an aggregate market value of $1,968,223.83, and records prior sales by the same person. The shares to be sold were acquired as restricted stock that vested in November 2021 in four tranches (1,899; 10,935; 689; 1,780). The filing lists a prior sale by Robert W. McMahon of 28,081 shares on 08/29/2025 for gross proceeds of $3,508,994.14. The notice includes the seller's certification that they are not aware of undisclosed material adverse information about the issuer.
Padraig McDonnell, who is listed as President and CEO and a Director of Agilent Technologies (A), reported a sale of 2,000 shares of Agilent common stock on 09/02/2025 at a reported price of $124.88 per share. After the transaction McDonnell beneficially owned 33,448 shares. The filing notes the sale was executed pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 28, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. McDonnell and filed on 09/04/2025.
Form 144 filing for Agilent Technologies, Inc. (A): The filer notified an intended sale of 2,000 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $249,760.00, with an approximate sale date of 09/02/2025 on the NYSE. The schedule lists the acquisition of smaller blocks of restricted stock that vested between 11/14/2023 and 05/19/2024 (totaling 2,000 shares listed). The filing also discloses two prior sales by the same person in 07/2025 (1,508 shares) and 08/2025 (2,000 shares) with gross proceeds shown.
Agilent Technologies (A) reported condensed, unaudited quarterly results for the three and nine months ended July 31, 2025, prepared under U.S. GAAP and recast to reflect a new three-segment structure: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets.
Services and other revenue grew 11% for the quarter and 9% year-to-date, driven by contract repair, preventative maintenance and on-demand services. Income from operations rose $4 million (3%) for the quarter and $21 million (6%) year-to-date on revenue increases, while operating margins faced near-term pressure from increased tariffs, shipping costs, unfavorable mix, warranty and variable pay. No goodwill impairment was indicated after quantitative testing. The company repurchased shares under its repurchase programs and paid quarterly dividends; commercial paper outstanding was $55 million at a 4.55% weighted average rate.
Agilent Technologies (A) Form 144 notice shows a proposed sale of 28,081 common shares via Fidelity Brokerage Services on the NYSE with an aggregate market value of $3,508,993.30. The filing lists two option-originated lots: 22,898 shares from an option granted 11/17/2020 and 5,183 shares from an option granted 11/22/2023, both indicated as to be sold on 08/29/2025 for cash. The filer reports 284,064,728 shares outstanding and no sales by the same person in the past three months. The notice contains the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Agilent Technologies Inc. (A) Form 144 shows a proposed sale of 21,644 common shares through Fidelity Brokerage Services with an aggregate market value of $2,706,365.76. The shares represent a small fraction of the 284,064,728 shares outstanding and the approximate sale date is 08/29/2025 on the NYSE. The shares to be sold were acquired upon option exercises dated 11/17/2020, 05/03/2022, and 11/22/2023, and payment is indicated as cash. The filer states there are no undisclosed material adverse facts and reports no securities sold in the past three months.
Agilent Technologies filed a Form 8-K reporting that on August 27, 2025 it issued a press release announcing financial results for the third fiscal quarter ended July 31, 2025. The filing states the press release is attached as Exhibit 99.1 and that the Exhibit is furnished, not "filed." The company explains it provides non-GAAP financial measures to supplement GAAP results, saying these measures exclude items such as restructuring and amortization and are used by management to evaluate segment and enterprise performance. The filing notes non-GAAP reconciliations and additional explanation appear in Exhibit 99.1.
Agilent Technologies reported the resignation of Robert W. McMahon from his role as Senior Vice President and Chief Financial Officer and named Rodney Gonsalves as interim Chief Financial Officer and interim Principal Financial Officer.
The Compensation Committee approved a bi-weekly salary stipend of $8,654 effective July 31, 2025 while Mr. Gonsalves serves as interim CFO and a grant of restricted stock units in a target amount of $1,000,000, subject to Agilent's standard equity award terms under its 2018 Stock Plan.